News – Page 500 – Endpoints News

CBO projects Senate drug pricing bill would cut the development of 10 drugs over 30 years

3 years ago

Covid-19 roundup: EMA recommends an additional booster dose; Moderna touts shot targeting Omicron subvariants

3 years ago

Updated: Different way to go after KRAS mutant tumors? Novo-backed biotech nabs $50M to wrap early studies

3 years ago

Vertex nabs ViaCyte's rival diabetes stem cell treatment, acquiring the biotech for $320M in cash

3 years ago

Ionis hands off an antisense drug for kidney disease, giving all rights to Roche

3 years ago

Florida Gov. DeSantis hints at suing FDA over stalled Canadian drug import plan

3 years ago

La Jolla exits to Innoviva in a deal that caps 33 years marked by misses in lupus, malaria and beta thalassemia

3 years ago

VC dollars keep rolling in as Qiming ties a ribbon on $2.5B Fund VIII

3 years ago

Two years after scrapping three hemophilia trials, Novo Nordisk plots route to FDA with new PhIII data

3 years ago

In wake of unexpected patient deaths, MacroGenics closes down PhII cancer trial

3 years ago

Sanofi’s next-gen hemophilia drugs take a PhIII bow — but can they still make their mark at this stage?

3 years ago

Bispecific M&A reaches AstraZeneca; Countdown for Merck's big bid; Biotech buyout in savage times; and more

3 years ago

FDA says it won't allow state-licensed pharmacists to prescribe Merck's Lagevrio

3 years ago

Horizon nabs FDA expanded label for gout med Krystexxa

3 years ago

Sinopharm mulls $1B buyout of China-based DNA synthesis company — report

3 years ago

Another Indian drug manufacturer hit with a Form 483 over recent observations

3 years ago

German chemicals company to expand its reach into mRNA ingredient production

3 years ago

Certain discarded drugs will soon cost pharma companies

3 years ago

Trio of biotechs raise funds to make enzymes and develop drugs for IBS and other autoimmune diseases

3 years ago

Korean diagnostics biotech goes transpacific, agreeing to shell out $1.5B to take Meridian private

3 years ago

Athersys’ woes continue as Aspire Capital axes its relationship with the biotech

3 years ago

Despite plenty of bears and little investor appetite, three biotechs beef up 2022's private placement lows

3 years ago

A portrait of a biotech buyout deal in savage times: turning a $15.50 offer into a $7.12 deal

3 years ago

Compassionate Use/Expanded Access programs: Three steps to improve their implementation for the benefit of all

3 years ago

First page Previous page 497 498 499500501 502 503 Next page Last page